Charité - Universitätsmedizin Berlin

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? (2020) Atreya R, Neurath M, Siegmund B Journal article, Review article The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany (2020) Petersen A, Bressem K, Albrecht J, Thiess HM, Vahldiek J, Hamm B, Makowski MR, et al. Journal article Evaluation of myocardial gene expression profiling for superior diagnosis of idiopathic giant-cell myocarditis and clinical feasibility in a large cohort of patients with acute cardiac decompensation (2020) Escher F, Pietsch H, Aleshcheva G, Wenzel P, Fruhwald F, Stumpf C, Westermann D, et al. Journal article Quantitative MRI for Assessment of Treatment Outcomes in a Rabbit VX2 Hepatic Tumor Model (2020) Keller S, Chapiro J, Brangsch J, Reimann C, Collettini F, Sack I, Savic LJ, et al. Journal article, Review article Effect Of Sunitinib Treatment On Skin Sodium Accumulation In Patients With Metastatic Renal Cancer: A Pilot Study (2020) Marko L, Dorr A, Linz P, Van Den Meiracker HA, Kuhne T, Dechend R, Danser JH, et al. Conference contribution In Vivo Validation of Spray-Dried Mesoporous Bioactive Glass Microspheres Acting as Prolonged Local Release Systems for BMP-2 to Support Bone Regeneration (2020) Berkmann JC, Herrera Martin AX, Pontremoli C, Zheng K, Bucher CH, Ellinghaus A, Boccaccini AR, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al. Conference contribution Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) Berking C, Schadendorf D, Weichenthal M, Eigentler T, Mohr P, Schober K, Kiecker F, et al. Conference contribution